Oramed Pharm (ORMP) Stock Statistics & Valuation Metrics

Oramed Pharm has a market cap or net worth of $138.33M. The enterprise value is $93.20M.

Oramed Pharm has 40,446,180 shares outstanding. The number of shares has decreased by -2.65% in one year.

Oramed Pharm’s return on equity (ROE) is 0.38 and return on invested capital (ROIC) is -19.15%.

The current PE Ratio of Oramed Pharm is 1.6. Oramed Pharm’s PEG ratio is -0.00368.

In the last 12 months, Oramed Pharm had revenue of 2.00M and earned 75.32M in profits. Earnings per share was 1.53.

In the last 12 months, operating cash flow was -13.12M and capital expenditures -11.32K, giving a free cash flow of -13.13M billion.

Oramed Pharm pays an annual dividend of ―, resulting in a dividend yield of ―

Oramed Pharm upcoming earnings date is Jul 15, 2026, TBA (Confirmed).

Oramed Pharm as a current ratio of 6.98, with Debt / Equity ratio of 0.41%

In the past 12 months, Oramed Pharm has paid 0.00 in taxes.

Oramed Pharm EV to EBITDA ratio is -4.83, with an EV/FCF ratio of -7.96.

Oramed Pharm has $51.36M in cash and marketable securities with $825.00K in debt, giving a net cash position of $50.54M billion.

Gross margin is 0.65%, with operating margin of -754.40%, and net profit margin of 3766.20%.

The average price target for Oramed Pharm is ―, which is 11.43% higher than the current price. The consensus rating is ―